MOREPENLABMorepen Laboratories Ltd.

    Morepen Laboratories gets IVR A/ Stable rating upgrade on bank facilities

    • Credit rating
    • Pharmaceuticals

    Morepen Laboratories (NSE: MOREPENLAB) had its bank facilities upgraded by Infomerics Valuation and Rating Limited to IVR A/ Stable, it said in a filing on 14 Nov 2026. The letter from the agency is dated 13 Nov 2026. The filing does not state the amount of the facilities rated.

    Key highlights

    • Rating assigned: IVR A/ Stable on bank facilities
    • Rating action: Rating upgraded
    • Agency letter dated 13 Nov 2026

    The rating action in numbers

    ItemDetail
    Rated entityMorepen Laboratories Ltd.
    InstrumentBank facilities
    RatingIVR A/ Stable
    ActionRating upgraded
    AgencyInfomerics Valuation and Rating Limited
    Agency letter dated13 Nov 2026
    Filed with exchanges14 Nov 2026

    What the rating covers and what it says

    Infomerics Valuation and Rating Limited, a SEBI registered credit rating agency, upgraded the rating of Morepen Laboratories' bank facilities to IVR A/ Stable. The filing names the rating and the action but gives no amount for the facilities covered.

    A rating outlook of Stable indicates the agency's view of the expected direction of the rating over time. The filing reports the outlook as Stable and does not describe any change in the agency's expectations beyond the upgrade itself.

    The upgrade alongside the company's recent results

    The company reported consolidated total income of ₹755.19 crore for Q2 FY27, up 81.4% year on year, and consolidated net profit of ₹88.89 crore, up 116.6%. Those results were reported separately and are not part of this filing.

    The filing gives no previous rating grade, so it does not show how far the upgrade moved the rating.

    What the rating upgrade means for Morepen Laboratories' shareholders

    The filing reports a change in the rating on the company's bank facilities and nothing else about its borrowings or operations. The company's market value was ₹5,459 crore at the 13 Nov 2026 close of ₹99.64 a share.

    Not stated in the filing: the amount of the bank facilities rated, the previous grade, and the reasons Infomerics gave for the upgrade. The filing also gives no date for any further rating review.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Morepen Laboratories Ltd. articles